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Background:  Recently,  much  attention  has  been  focused  on  cardio-renal  interaction.  Urinary  liver-type
fatty  acid  binding  protein  (U-L-FABP),  which  is  produced  in the  proximal  tubule  by renal  hypoxia  and
oxidative  stress,  has  been  identiﬁed  as  a  useful  marker  for diagnosis  of  acute  kidney  disease  and  a
predictor  of  future  events  in  chronic  kidney  disease.  However,  the  clinical  signiﬁcance  of  U-L-FABP
measurements  in patients  with  acute  coronary  syndrome  (ACS)  has  not  been  completely  evaluated.
Methods  and results:  This  study  included  50  consecutive  patients  with  ACS [37  with  acute  myocardial
infarction  (AMI)  and  13 with  unstable  angina  pectoris  (UAP)]  and  47 subjects  without  coronary  artery
disease  (control  group).  U-L-FABP  levels,  urinary  albumin  (U-Alb),  and  other  serum  parameters  were
measured  at  admission  and  at 24 h  after  percutaneous  coronary  intervention.
Results:  U-L-FABP  levels  in  patients  with  AMI  were  signiﬁcantly  higher  (p  =  0.0019),  than  in  control
subjects,  while  patients  with  UAP  did  not  exhibit  such  an  increase.  U-L-FABP  levels  at  admission
were  positively  correlated  with  brain  natriuretic  protein  levels  (p = 0.001)  and  duration  of hospitaliza-
tion  (p = 0.025).  At follow-up  angiography,  patients  with  restenosis  had  signiﬁcantly  higher  U-L-FABP
(p  =  0.047)  and  U-Alb  levels  (p < 0.0001)  than  those  without  restenosis.  After  a median  follow-up  of  42
months,  U-L-FABP  levels  at second  measurement  in patients  with major  adverse  cardiocerebrovascu-
lar  events  (MACCEs)  were  signiﬁcantly  higher  than those  in  patients  without  MACCEs  (p =  0.028).  After
adjusting  for  confounding  factors,  high  U-L-FABP  levels  at second  measurement  were  found  to  be  inde-
pendent  factors  for MACCEs  (p  =  0.019).
Conclusions:  These  data  suggest  that  patients  with  ACS,  especially  those  with  AMI,  have  high  U-L-FABP
levels,  and  that  U-L-FABP  measurements  may  be  useful  in identifying  high-risk  patients  for  future  car-
diovascular  events  after  ACS.
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Observational studies and clinical trials have shown that acute
nd chronic kidney injuries initiate and accelerate cardiovascu-
ar diseases [1–5]. Decreased glomerular ﬁltration rates (GFRs)
re closely associated with hospitalization risk and mortality in
atients with coronary artery disease (CAD) [3].  If cardiac and
idney dysfunctions co-exist, the risk of cardiovascular events
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increases by 1.5–3.5 fold [6].  Hence, much attention has been
focused on the cardio-renal interaction.
Fatty acid binding proteins (FABPs) are 15 kDa proteins that
belong to the lipocalin family. The following 9 different FABPs with
tissue-speciﬁc distribution have been identiﬁed: L (liver), I (intesti-
nal), H (muscle and heart), A (adipocyte), E (epidermal), Il (ileal), B
(brain), M (myelin), and T (testis) [7].  In the human kidney, 2 types
of FABP have been identiﬁed; the liver-type FABP (L-FABP) is pro-
duced in the proximal tubule and the heart-type FABP is produced
in the distal tubule [8]. Urinary L-FABP (U-L-FABP) binds free FAs
(FFAs) produced by proteinuria, oxidative stress, and toxic insults
[9]. U-L-FABP could potentially prevent FFA-induced tubulointer-
stitial damage. Traditional markers of kidney dysfunction, such as
albuminuria and creatinine clearance, are based on the distant pro-
duction of an endogenous marker and its subsequent ﬁltration,
vier Ltd. All rights reserved.
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ecretion, and/or resorption by the kidney. All of these conventional
arkers indirectly estimate kidney function. In contrast, U-L-FABP
ndicates kidney injury by directly measuring protein levels [10].
ecent studies have shown that U-L-FABP may  be a useful marker
f acute and progressive renal disease [11,12],  however, the clin-
cal signiﬁcance of U-L-FABP measurement in patients with CAD
as not been completely investigated. A recent study demonstrated
he clinical beneﬁt of U-L-FABP measurement for the diagnosis
f ACS [13], but to date, there are no data evaluating the clinical
igniﬁcance of U-L-FABP measurement in predicting future cardio-
ascular events in patients with ACS. Therefore, we  investigated
-L-FABP levels in patients with ACS, including those with acute
yocardial infarction (AMI) and unstable angina pectoris (UAP).
n addition, we assessed whether U-L-FABP measurement could
dentify patients at high risk of future cardiovascular events.
ethods
tudy subjects
Fifty consecutive patients (39 male, mean age 64 ± 12 years)
ith ACS (37 with AMI, and 13 with UAP) who underwent primary
ercutaneous coronary intervention (PCI) between April 2007 and
pril 2008 at Juntendo University Hospital were enrolled in this
tudy. Forty seven subjects in an outpatient clinic (33 male, mean
ge 60 ± 13 years) were included as the control group. Control sub-
ects had no history of CAD and no evidence of coronary ischemia
xamined by stress cardiac testing. ACS was deﬁned by high-risk
AP, non-ST elevation MI  (NSTEMI), or ST elevation MI  (STEMI).
lectrocardiographic criteria for the diagnosis of STEMI/NSTEMI
ere as follows: (1) persistent (>20 min) ST elevation in contiguous
eads with cut-off points ≥0.2 mV  in men  or ≥0.15 mV in women  in
eads V2–V3 and/or ≥0.1 mV  in other leads in both sexes; (2) new ST
epression horizontal or down-sloping ≥ 0.05 mV  in 2 contiguous
eads, and/or T inversion ≥ 0.1 mV  in two leads in prominent R wave
r R/S ratio > 1.3; (3) new detection of complete left bundle branch
lock; and (4) increase (≥2 fold) in serum creatine phosphokinase
nd troponin T positivity. Patients with cardiac shock, acute renal
isease, end-stage renal failure requiring dialysis, an estimated
FR (eGFR) < 50 mL/min/1.73 m2, hepatic dysfunction, collagen dis-
ase, and those using nonsteroidal anti-inﬂammatory drugs were
xcluded. None of the control subjects had a history of cardio-
ascular disorders or systemic inﬂammatory diseases. The ethical
ommittee of Juntendo University, School of Medicine approved the
tudy protocol and written informed consent was obtained from all
ubjects.
nalyses of urine and blood samples
Urine samples were collected just before and 24 h after PCI
n the ACS group and at the time of clinic visit in the control
roup. All samples were stored at −20 ◦C until analysis. U-L-FABP
evels were measured using a two-step sandwich enzyme-linked
mmunosorbent assay (CMIC, Tokyo, Japan). Urinary albumin (U-
lb) levels were measured by immunoturbidimetry and adjusted
y urinary creatinine (U-Cr). Because U-L-FABP/U-Cr was  not nor-
ally distributed, the value was expressed as the log-normal
istribution of the ratio of U-L-FABP to U-Cr (U-L-FABP/U-Cr).
ther serum parameters were measured for all subjects, at the
ame time urine samples were taken. Serum creatinine, troponin-
, creatinine phosphokinase, high sensitive C-reactive protein
hsCRP), and brain natriuretic protein (BNP) levels were ana-
yzed by standard methods [14]. The eGFR was calculated using
he following equation: eGFR = 194 × age−0.287 × Cre−1.094 × 0.739
if female), according to the Modiﬁcation of Diet in Renal Diseasediology 60 (2012) 168–173 169
Study [15]. Total cholesterol, triglyceride, and high-density lipopro-
tein cholesterol (HDL-C) levels were also measured by standard
methods. Low-density lipoprotein cholesterol levels were calcu-
lated by Friedewald’s formula. Hemoglobin (Hb) A1c (JDS) (%) was
measured as previously described Japanese standard substance
and measurement methods and NGSP criteria for measurement of
HbA1c.
PCI and antiplatelet therapy
The intervention procedure was performed according to the
standard technique of each operator, as previously described
[16,17]. The endpoint of the procedure for the main vessel was
thrombolysis in myocardial infarction 3 and the absence of major
dissections that would compromise ﬂow in the vessel. Intravenous
unfractionated heparin was administered before PCI. All patients
in the ACS group were implanted with bare-metal stents. Follow-
up coronary angiography was performed 6–8 months after stent
implantation. A technician without any knowledge of the study
results performed all the quantitative coronary angiography (QCA)
analyses, as previously described [18]. The absolute values for
the mean reference diameter and minimal luminal diameter were
determined. Angiographic restenosis was  deﬁned as a diameter
stenosis ≥ 50% at the follow-up angiography as determined by QCA
analysis. Patients in the ACS group received dual antiplatelet ther-
apy of clopidogrel (300 mg  loading dose, followed by 75 mg  daily)
and aspirin (200 mg  loading dose and 100 mg  daily throughout the
study period). All patients in the ACS group were followed for up to
54 months (median 42 months). Major adverse cardiocerebrovas-
cular events (MACCEs) were deﬁned as all-cause death, nonfatal MI,
UAP, revascularization for target lesion or new lesion, and admis-
sion for stroke.
Statistical analysis
Statistical analysis was performed with Stat View 5.0 MDSU sta-
tistical software (SAS Institute, Cary, NC, USA). Data are presented
as means ± standard deviations (SD). Linear regression analysis was
used to evaluate the correlation between the 2 variables. p < 0.05
was considered statistically signiﬁcant. Categorical and continuous
variables were compared by a chi-square analysis. Cox proportional
hazard analysis was  performed to identify independent predic-
tors for the MACCEs including age, gender, body mass index (BMI),
diabetes mellitus, hypertension, dyslipidemia, eGFR, and log (U-L-
FABP/U-Cr) levels.
Results
Characteristics of study subjects
Table 1 summarizes the baseline characteristics of each group.
There were no signiﬁcant differences in age, gender, BMI, blood
pressure, serum glucose proﬁles, and eGFR between the ACS and
the control groups. Serum BNP and hsCRP levels in the ACS group
were signiﬁcantly higher than those in the control group (p < 0.005,
p < 0.05, respectively). HDL-C levels in the ACS group were sig-
niﬁcantly lower than those in the control group (p < 0.005). The
ACS group had signiﬁcantly higher prevalence of dyslipidemia
(p < 0.005), metabolic syndrome (p < 0.005), and smoking (p < 0.005)
and signiﬁcantly higher levels of waist circumference (p < 0.05)
than the control group. Concomitant use of beta-blockers and
statins was  more frequent in the ACS group than in the control
group (p < 0.05, p < 0.005, respectively). There were no signiﬁcant
differences in use of angiotensin-converting enzyme inhibitors
(ACEIs), angiotensin receptor blockers (ARBs), calcium-channel
blockers (CCBs), and anti-diabetic agents between the two groups.
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Table 1
Comparison of clinical characteristics between the control and the ACS groups.
Control ACS ACS
AMI  UAP
n 47 50 37 13
Age,  years 60 ± 13.0  64 ± 11.9  64 ± 12.4  63 ± 11.3
Male  (%) 33(70) 39(78) 27(73) 12(92)
Body  mass index, kg/m2 22.7 ± 2.2 23.7 ± 3.5 23.8 ± 3.4 23.4 ± 3.0
Waist  circumference, cm 78.2 ± 2.56 87.7 ± 8.9* 88.2 ± 9.4* 87.9 ± 8.3*
Systolic blood pressure, mmHg 129 ± 21 125 ± 21 123 ± 21 128 ± 21
Dyastolic blood pressure, mmHg  71 ± 13 73 ± 13 72 ± 14 74 ± 9
Hypertension (%) 25(53) 31(62) 21(57) 10(77)
Diabetes mellitus (%) 7(15) 14(28) 10(27) 4(31)
Dyslipidemia (%) 11(23) 35(70)** 23(62)** 12(92)** ,+
Metabolic syndrome (%) 5(11) 18(36)** 12(32)* 6(46)** ,+
Smoker (%) 5(11) 28(56)** 19(51)** 9(69)**
Estimated GFR, ml/min/1.73 m2 81.7 ± 26.8 80.2 ± 17.7 79.1 ± 17.0 80.9 ± 7.4
Total  cholesterol (mg/dl) 178 ± 38 185 ± 32 188 ± 28 182 ± 38
Triglyceride (mg/dl) 130 ± 32 123 ± 60 122 ± 67 124 ± 41
HDL-cholesterol, mg/dl 51 ± 12 44 ± 11** 43 ± 9** 47 ± 14
LDL-cholesterol, mg/dl 111 ± 32 108 ± 39 112 ± 42 98 ± 24
Blood  glucose, mg/dl 105 ± 35 116 ± 38 114 ± 36 117 ± 39
HbA1c,  % (JDS) 5.6 ± 0.7 5.6 ± 0.9 5.7 ± 0.8 5.6 ± 1.0
BNP,  pg/mL 49 ± 38 294 ± 249** 338 ± 318** 245 ± 114**
hsCRP, mg/dL 0.059 ± 0.039 2.835 ± 1.541* 3.157 ± 1.794* 2.576 ± 1.466*
Ejection fraction, % (−) 56.9 ± 10.6 55.1 ± 9.4 60.1 ± 13.1
Number of diseased vessels
One (%) (−) 24(48) 17(45) 7(55)
Two  (%) (−) 18(36) 16(43) 2(15)
Three  (%) (−) 8(16) 4(11) 4(30)
Use  of medication
ACEI/ARB (%) 25(53) 29(58) 25(68) 4(31)
Beta-blockers (%) 16(34) 27(54)* 21(57)* 6(46)+
Statins (%) 11(23) 33(66)** 26(70)** 7(54)*
Values are mean ± SD.
ACS, acute coronary syndrome; AMI, acute myocardial infarction; UAP, unstable angina pectoris; GFR, glomerular ﬁltration rate; HDL, high-density lipoprotein. LDL, low-
density  lipoprotein; HbA1c, hemoglobin A1c; JDS, Japan Diabetes Society. BNP, brain natriuretic protein; hsCRP, high sensitive C-reactive protein. ACEI, angiotensin-converting
enzyme inhibitors; ARB, angiotensin receptor blockers.
* p < 0.05 vs. control.
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Fig. 1. Comparison of U-L-FABP levels between the ACS (AMI and UAP) and the con-
trol  groups. Log (U-L-FABP/U-Cr) levels in the ACS group (n = 50) were signiﬁcantly** p < 0.005 vs. control.
+ p < 0.05 vs. AMI.
one of the patients who underwent angiography showed contrast
edium-induced nephropathy, as deﬁned by Harjai et al. [19].
-L-FABP levels in the ACS and the control groups
Log (U-L-FABP/U-Cr) levels for each group are shown in
ig. 1. Before angiography, log (U-L-FABP/U-Cr) levels in the ACS
roup were signiﬁcantly higher than those in the control group
p = 0.0024). In addition, log (U-L-FABP/U-Cr) levels in patients with
MI  (p = 0.0018), but not in those with UAP, were signiﬁcantly
igher than those in control subjects.
Next, the correlations between log (U-L-FABP/U-Cr) levels and
ther serum parameters were analyzed. Log (U-L-FABP/U-Cr) lev-
ls positively correlated with log BNP levels (r = 0.323, p = 0.001;
ig. 2A). U-L-FABP levels have been reported to be positively cor-
elated with U-Alb levels [20]. Our data also revealed a positive
orrelation between log (U-L-FABP/U-Cr) and U-Alb/U-Cr levels
r = 0.500, p < 0.0001) (Fig. 2B). In addition, no signiﬁcant correlation
as found between log (U-L-FABP/U-Cr) levels and other serum
arameters (data not shown). Interestingly, duration of hospital-
zation was positively correlated with log (U-L-FABP/U-Cr) levels
r = 0.296, p = 0.025) (Fig. 2C).
ollow-up data in the ACS groupFollow-up angiography was performed in 49 patients (98%).
ne patient refused angiographic follow-up, because of absence
f angina and negative exercise testing. Angiographic in-stent
higher than those in the control group (n = 47) (p = 0.0024). Log (U-L-FABP/U-Cr) lev-
els in patients with AMI  (n = 37), but not in those with UAP (n = 13), were signiﬁcantly
higher (p = 0.0019) than those in the control group. ACS, acute coronary syndrome;
AMI, acute myocardial infarction; UAP, unstable angina pectoris; U-L-FABP, urinary
liver-type fatty acid-binding protein; U-Cr, urinary creatinine.
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ig. 3. U-L-FABP and U-Alb levels in patients with and without in-stent restenosis at follow
og  (U-L-FABP/U-Cr) levels than the restenosis (−) group (p = 0.047). (B) The restenosis (+)
p  < 0.0001). U-L-FABP, urinary liver-type fatty acid-binding protein; U-Cr, urinary creatin/U-Cr levels (r = 0.500, p < 0.0001) (n = 97). (C) A positive correlation was observed
 = 50). BNP, brain natriuretic protein; U-L-FABP, urinary liver-type fatty acid-binding
 pectoris.(p = 0.047, p < 0.0001, respectively) (Fig. 3A and B). MACCEs were
observed in 9 patients (nonfatal MI  1 patient and revasculari-
zation 8 patients). At second measurement, log (U-L-FABP/U-Cr)
levels in the MACCE (+) group were signiﬁcantly higher than
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ine; U-Alb, urinary albumin.
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hose in the MACCE (−) group (p = 0.028) (Fig. 4). Meanwhile, log
U-L-FABP/U-Cr) levels at admission were not signiﬁcantly differ-
nt between the MACCE (+) and MACCE (−) groups. The levels
f eGFR before PCI in the MACCE (+) and MACCE (−) groups
ere 81.3 ± 15.8 ml/min/1.73 m2 and 82.9 ± 17.3 ml/min/1.73 m2,
espectively. The levels of eGFR after PCI in the MACCE (+)
nd MACCE (−) groups were 78.8 ± 14.1 ml/min/1.73 m2 and
0.8 ± 13.3 ml/min/1.73 m2, respectively. There was  no signiﬁcant
ifference in eGFR before and after PCI between the two groups.
here were no signiﬁcant differences in risk factors between the
wo groups. In addition, there was no difference between these
roups regarding the concomitant use of medications, includ-
ng anti-platelet drugs, beta-blockers, CCBs, ACEIs, ARBs, insulin,
eroxisome proliferator-activated receptor (PPAR)- agonists, or
tatins. After adjustment for age, gender, BMI, diabetes mellitus,
ypertension, dyslipidemia, and eGFR, multivariate Cox propor-
ional hazard analysis revealed that log (U-L-FABP/U-Cr) levels
ere signiﬁcant and independent factors for MACCEs (p = 0.019).
iscussion
This study demonstrated that U-L-FABP levels in patients with
MI, but not in patients with UAP, were signiﬁcantly higher than
hose in the control subjects. In addition, U-L-FABP levels were
ndependent factors for MACCEs in patients with ACS. To the best of
ur knowledge, this is the ﬁrst report that demonstrates the signif-
cance of U-L-FABP measurement in identifying high-risk subjects
mong patients with ACS.
The potential reasons why U-L-FABP levels in patients with AMI,
ut not in patients with UAP, were signiﬁcantly higher than those
n controls should be discussed. Fukuda et al. [13] reported a sig-
iﬁcant difference in log (U-L-FABP/U-Cr) levels between the ACS
roup and the stable AP (SAP) groups, and that log (U-L-FABP/U-
r) may  be a useful marker for the diagnosis of ACS. However, the
ifference in U-L-FABP levels between the AMI  and the UAP groups
ad not been elucidated, because the previous study did not dis-
riminate between AMI  and UAP. L-FABP is an intracellular lipid
haperone that selectively binds unsaturated FAs or lipid peroxida-
ion products and transports them to mitochondria or peroxisomes,
here they are metabolized by -oxidization [21]. FAs are impor-
ant in mammals as mediators of signal transduction for metabolicdiology 60 (2012) 168–173
regulation and are rarely present in the free state in biological
ﬂuids, because of their hydrophobic character and cytotoxicity.
Overproduction of FFAs induces oxidative stress and production of
inﬂammatory cytokines by increasing mitochondrial reactive oxy-
gen species, and subsequently leads to tubulointerstitial damage
[22]. It is well established that FFA levels are increased in AMI  [23]
and renal ischemia [24]. Therefore, U-L-FABP levels may  be high
especially in patients with AMI.
This study also demonstrated the novel ﬁndings that U-L-FABP
levels at admission positively correlated with BNP levels and dura-
tion of hospitalization, and that U-L-FABP levels 24 h after primary
PCI were associated with future cardiovascular events. Difference
in U-L-FABP and peak CK levels was  not statistically signiﬁcant
(Supplement Fig. 1A), however, troponin T levels were positively
correlated with U-L-FABP levels in the AMI  group (Supplement
Fig. 1B). Moreover, positive correlations between U-L-FABP levels,
BNP levels, and duration of hospitalization may indicate the extent
of cardiac injury, as discussed above. In the follow-up study, the
restenosis (+) group showed signiﬁcantly higher log (U-L-FABP/U-
Cr) and U-Alb/U-Cr levels at admission than those in the restenosis
(−) group. We  evaluated whether the clinical and lesion charac-
teristics could affect the incidence of restenosis between the two
groups. The restenosis (+) group included only patients with AMI,
and showed higher prevalence of hypertension, dyslipidemia, and
current smoking (data not shown). Although lesion characteristics
did not show signiﬁcant difference between the two  groups, the dif-
ference in clinical characteristics may  contribute to an increase in
hyperplasia at PCI site, and subsequently lead to restenosis. Further
investigations are required to assess these points.
The fact that U-L-FABP levels 24 h after primary PCI, but not at
admission, helps in identifying high-risk patients for future car-
diovascular events is intriguing. A previous study showed that
unbound serum FFAs levels immediately after PCI were 14-fold
higher than those before PCI [25]. Moreover, U-L-FABP levels 24 h
after PCI remained high in patients with ACS and even in patients
with SAP [13]. Increased and/or sustained U-L-FABP levels 24 h after
primary PCI may  indicate not only oxidative stress and an inﬂam-
matory state caused by cardiac injury, but also coronary damage,
including at the PCI site. Excessive damage and healing could induce
hyperplasia at the PCI site, and subsequently lead to restenosis.
In addition, increased oxidative stress accounts for a signiﬁcant
proportion of endothelial dysfunction, which is impaired in CAD,
especially in ACS [26]. Endothelial dysfunction and FFA overload
may  play an important role in the pathogenesis of ACS and increase
U-L-FABP levels, although no clear evidence has been reported that
characterizes the relationship between cardiac injury and tubuloin-
terstitial injury. Moreover, several lines of evidence indicate that
activation of L-FABP in proximal tubules could be triggered not only
by overproduction of FFAs, but also by tubular ischemia [27]. Sys-
temic hypoxia caused by ACS induces both renal parenchymal and
tubulointerstitial ischemia. Hypoxia is correlated with transcrip-
tional activation of L-FABP because the promoter region of L-FABP
contains the binding sites of hepatocyte nuclear factor, hypoxia-
inducible factor-1, and PPARs [28].
Despite the novel ﬁndings, our study has the following limita-
tions. First, the sample size was  small, which limited our ability
to determine signiﬁcance. In addition, second urine samples were
obtained 24 h after PCI from 20 (17 patients with AMI  and 3 with
UAP) of the 41 patients without MACCE. Clinical and angiographic
characteristics, including history of AMI  and UAP, were not sig-
niﬁcantly different between the 20 patients from whom second
samples were obtained and the 21 patients from whom second
samples were not obtained 24 h after PCI. Further investigations
with larger sample sizes are needed to clarify our ﬁndings and
elucidate precise mechanisms. Second, we did not measure U-L-
FABP levels during a further follow-up period. Third, U-L-FABP
 of Car
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evels can be affected by treatment with various medications,
uch as ACEIs or ARBs [29], statins [30], and PPAR agonists
31]. However, no signiﬁcant differences in concomitant use of
uch medications were observed between the AMI  and the UAP
roups or between the MACCE (+) and MACCE (−) groups. Finally,
e expected that U-L-FABP levels must be increased in patients
ith contrast medium-induced nephropathy, however, none of the
atients who underwent angiography exhibited contrast medium-
nduced nephropathy.
onclusions
These results demonstrated that patients with ACS, especially
hose with AMI, had high U-L-FABP levels, and that urinary L-FABP
easurement may  help to identify high-risk patients for future
ardiovascular events after ACS.
ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jjcc.2012.03.008.
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